Beneficial efficacy for type 2 diabetes (T2D) and Metabolic syndrome (Met-S) by vildagliptin/metformin (EquMet)

Bando M, Takeuchi Y, Okumura M, Nagao N, Sakai K, Kimoto Y and Bando H

Published on: 2023-06-28

Abstract

The case is 51-year-old female with obesity, type 2 diabetes (T2D) and hypertension with BMI 31.4 kg/m². She has been treated by oral hypoglycemic agents (OHAs) and anti-hypertensive agents (AHAs). From January 2020, vildagliptin and metformin (EquMet) was initiated, and she showed HbA1c decrease 7.9% to 6.3%, weight reduction 74,0kg to 68.9kg, ALT 99 U/L to 19U/L and LDL 154mg/dL to 85mg/dL, suggesting clinical efficacy. Furthermore, improved findings of ECG and sleep apnea syndrome (SAS) have been found, in which general signs and symptoms of Metabolic syndrome (Met-S) were relieved. She has felt no gastro-intestinal adverse effects (GIAEs).